Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • EU cracks down on...

    EU cracks down on Valsartan- blood pressure medicine made by Mylan

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-20T12:05:34+05:30  |  Updated On 20 Nov 2018 12:05 PM IST
    EU cracks down on Valsartan- blood pressure medicine made by Mylan




    The batches of Valsartan were found to contain N-nitrosodiethylamine (NDEA), a probable carcinogen, and were made in Mylan's Hyderabad facility in India, the EMA said.

    EU: European Union authorities on Monday stepped in to effectively ban sales of blood pressure medicine valsartan made by an India-based unit of Mylan NV after some batches were found to contain a probable cancer-causing impurity, the latest in a global crackdown.

    The European regulator said the unit's compliance certificate had been suspended, effectively prohibiting the use of its valsartan in medicines in the region.

    The affected batches are being recalled and tests conducted to determine the extent of the contamination, the European Medicines Agency said https://www.ema.europa.eu/en/news/valsartan-mylan-laboratories-india-can-no-longer-be-used-eu-medicines-due-ndea-impurity on Monday.

    The batches were found to contain N-nitrosodiethylamine (NDEA), a probable carcinogen, and were made in Mylan's Hyderabad facility in India, the EMA said.

    Cancer-causing impurities have been linked to batches of valsartan over the past year, leading to a global recall.

    The U.S. Food and Drug Administration last month halted imports of drug ingredients or medicines made with ingredients produced at a factory belonging to a Chinese bulk manufacturer of valsartan, Zhejiang Huahai Pharmaceuticals .

    Huahai has recalled valsartan products made at its factory in China's Chuannan province after N-nitrosodimethylamine (NDMA), another impurity linked to cancer, was found.

    Mylan did not immediately respond to a request for comment.

    (Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)

    Read Also: Cost of blood pressure drug surges in U.S. after recall






    banblood pressureblood pressure medicineBPBP medicinecancercarcinogenEMAMylanMylan HyderabadNDEANDMAnitrosodiethylaminepharmaceuticalUSFDAValsartanZhejiang Huahai
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok